NEUROENDOCRINE CARCINOMA side effect
What is NEUROENDOCRINE CARCINOMA ?
Help Community - Describe Your Side Effect
Search FDA Side Effects
Ask Health Expert
NEUROENDOCRINE CARCINOMA and Recently Reported Side Effects
NEUROENDOCRINE CARCINOMA and 15 most Active Side Effect polls
NEUROENDOCRINE CARCINOMA and featured health surveys
Substances toxic to Health
Recent Hospital reviews
Comments about Side Effects
Hospital Quality reviews
Homecare Quality reviews
Cisapride Side Effects Report #5411054-8
Physician from UNITED STATES reported CISAPRIDE problem on July 31, 2007. Female patient, weighting 114.0 lb, was diagnosed with gastrointestinal motility disorder, gastrooesophageal reflux disease, routine health maintenance, hypothyroidism, catheterisation venous, osteoporosis, iron deficiency, dyspepsia and was treated with CISAPRIDE. After drug was administered, patient experienced the following problems/side effects: catheter related infection, neuroendocrine carcinoma, staphylococcal sepsis, urinary tract infection, . CISAPRIDE dosage: unknown. During the same period patient was treated with LEVOTHYROXINE, COUMADIN, MIACALCIN, FERROUS SULPHATE, NEXIUM. Patient was hospitalized. Patient died.
Betaseron Side Effects Report #5401894-3
BETASERON problem was reported by a Physician from UNITED STATES on July 18, 2007. Female patient, 56 years of age, weighting 160.9 lb, was diagnosed with relapsing-remitting multiple sclerosis and was treated with BETASERON. After drug was administered, patient experienced the following problems/side effects: depression, neuroendocrine carcinoma, pancreatic neoplasm, . BETASERON dosage: unknown. During the same period patient was treated with PANCREASE MT, EFFEXOR, CLONAZEPAM, HYDROCHLOROTHIAZIDE, FERROUS SULPHATE, SYNTHROID, LAMICTAL, POTASSIUM CHLORIDE. Patient was hospitalized. Patient recovered.
Betaseron Side Effects Report #5401894-3
Physician from UNITED STATES reported BETASERON problem on July 18, 2007. Female patient, 56 years of age, weighting 160.9 lb, was diagnosed with relapsing-remitting multiple sclerosis and was treated with BETASERON. After drug was administered, patient experienced the following problems/side effects: depression, neuroendocrine carcinoma, pancreatic neoplasm, . BETASERON dosage: unknown. During the same period patient was treated with PANCREASE MT, EFFEXOR, CLONAZEPAM, HYDROCHLOROTHIAZIDE, FERROUS SULPHATE, SYNTHROID, LAMICTAL, POTASSIUM CHLORIDE. Patient was hospitalized. Patient recovered.
Betaseron Side Effects Report #5282625-7
BETASERON problem was reported by a Physician from UNITED STATES on Mar 19, 2007. Female patient, 56 years of age, weighting 160.9 lb, was diagnosed with relapsing-remitting multiple sclerosis and was treated with BETASERON. After drug was administered, patient experienced the following problems/side effects: depression, neuroendocrine carcinoma, pancreatic neoplasm, . BETASERON dosage: unknown. During the same period patient was treated with PANCREASE MT, EFFEXOR, CLONAZEPAM, HYDROCHLOROTHIAZIDE, FERROUS SULPHATE, SYNTHROID, LAMICTAL, POTASSIUM CHLORIDE. Patient was hospitalized. Patient recovered.
Follitropin Side Effects Report #5421619-5
Consumer or non-health professional from ITALY reported FOLLITROPIN BETA problem on Aug 13, 2007. Female patient, 36 years of age, was treated with FOLLITROPIN BETA. After drug was administered, patient experienced the following problems/side effects: adenocarcinoma pancreas, liver disorder, neuroendocrine carcinoma, pancreatic carcinoma, . FOLLITROPIN BETA dosage: unknown. During the same period patient was treated with CHRORIONIC GONADOTROPHIN, PROGESTERONE. Patient died.
Sandimmune Side Effects Report #5389451-9
SANDIMMUNE problem was reported by a Physician from GERMANY on July 12, 2007. Male patient, 60 years of age, weighting 154.3 lb, was diagnosed with liver transplant and was treated with SANDIMMUNE. After drug was administered, patient experienced the following problems/side effects: alanine aminotransferase increased, aspartate aminotransferase increased, neuroendocrine carcinoma, rash, ultrasound liver abnormal, . SANDIMMUNE dosage: 200 MG/DAILY. During the same period patient was treated with METHYLPREDNISOLONE. Patient was hospitalized. Patient died on 04/23/2007.
Sandimmune Side Effects Report #5389738-X
Physician from GERMANY reported SANDIMMUNE problem on July 12, 2007. Male patient, 60 years of age, weighting 154.3 lb, was diagnosed with liver transplant and was treated with SANDIMMUNE. After drug was administered, patient experienced the following problems/side effects: alanine aminotransferase increased, aspartate aminotransferase increased, neuroendocrine carcinoma, rash, ultrasound liver abnormal, . SANDIMMUNE dosage: 200 MG/DAILY. During the same period patient was treated with METHYLPREDNISOLONE. Patient was hospitalized. Patient died on 04/23/2007.
Sandimmune Side Effects Report #5389451-9
SANDIMMUNE problem was reported by a Physician from GERMANY on July 12, 2007. Male patient, 60 years of age, weighting 154.3 lb, was diagnosed with liver transplant and was treated with SANDIMMUNE. After drug was administered, patient experienced the following problems/side effects: alanine aminotransferase increased, aspartate aminotransferase increased, neuroendocrine carcinoma, rash, ultrasound liver abnormal, . SANDIMMUNE dosage: 200 MG/DAILY. During the same period patient was treated with METHYLPREDNISOLONE. Patient was hospitalized. Patient died on 04/23/2007.
Sandimmune Side Effects Report #5389738-X
Physician from GERMANY reported SANDIMMUNE problem on July 12, 2007. Male patient, 60 years of age, weighting 154.3 lb, was diagnosed with liver transplant and was treated with SANDIMMUNE. After drug was administered, patient experienced the following problems/side effects: alanine aminotransferase increased, aspartate aminotransferase increased, neuroendocrine carcinoma, rash, ultrasound liver abnormal, . SANDIMMUNE dosage: 200 MG/DAILY. During the same period patient was treated with METHYLPREDNISOLONE. Patient was hospitalized. Patient died on 04/23/2007.
Sutent Side Effects Report #5367956-4
SUTENT problem was reported by a Physician from BRAZIL on June 11, 2007. Female patient, 58 years of age, was diagnosed with neuroendocrine carcinoma and was treated with SUTENT. After drug was administered, patient experienced the following problems/side effects: disease progression, leukopenia, neuroendocrine carcinoma, thrombocytopenia, . SUTENT dosage: unknown. Patient was hospitalized. Patient died on 03/01/2007.